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Abstract
Introduction Cancer therapies directed at specific molecular
targets in signaling pathways of cancer cells, such as tamoxifen,
aromatase inhibitors and trastuzumab, have proven useful for
treatment of advanced breast cancers. However, increased risk
of endometrial cancer with long-term tamoxifen administration
and of bone fracture due to osteoporosis in postmenopausal
women undergoing aromatase inhibitor therapy are recognized
side effects. These side effects as well as drug resistance make
it necessary to search for novel molecular targets for drugs on
the basis of well-characterized mechanisms of action.
Methods Using accurate genome-wide expression profiles of
breast cancers, we found maternal embryonic leucine-zipper
kinase (MELK) to be significantly overexpressed in the great
majority of breast cancer cells. To assess whether MELK has a
role in mammary carcinogenesis, we knocked down the
expression of endogenous MELK  in breast cancer cell lines
using mammalian vector-based RNA interference. Furthermore,
we identified a long isoform of Bcl-G (Bcl-GL), a pro-apoptotic
member of the Bcl-2 family, as a possible substrate for MELK by
pull-down assay with recombinant wild-type and kinase-dead
MELK. Finally, we performed TUNEL assays and FACS analysis,
measuring proportions of apoptotic cells, to investigate whether
MELK is involved in the apoptosis cascade through the Bcl-GL-
related pathway.
Results Northern blot analyses on multiple human tissues and
cancer cell lines demonstrated that MELK was overexpressed at
a significantly high level in a great majority of breast cancers and
cell lines, but was not expressed in normal vital organs (heart,
liver, lung and kidney). Suppression of MELK  expression by
small interfering RNA significantly inhibited growth of human
breast cancer cells. We also found that MELK physically
interacted with Bcl-GL  through its amino-terminal region.
Immunocomplex kinase assay showed that Bcl-GL  was
specifically phosphorylated by MELK in vitro. TUNEL assays and
FACS analysis revealed that overexpression of wild-type MELK
suppressed Bcl-GL-induced apoptosis, while that of D150A-
MELK did not.
Conclusion Our findings suggest that the kinase activity of
MELK is likely to affect mammary carcinogenesis through
inhibition of the pro-apoptotic function of Bcl-GL. The kinase
activity of MELK could be a promising molecular target for
development of therapy for patients with breast cancers.
Introduction
Breast cancer is one of the leading causes of cancer death in
women worldwide. According to a 2002 estimate, more than
1,100,000 patients were newly diagnosed with breast cancer,
and approximately 410,000 patients died of the disease [1].
Recent improvements in detecting breast cancer at an early
stage through mammographic screening have contributed to
a decrease in breast cancer-associated mortality. Mastectomy
is among the first options for treatment of localized breast can-
cer. Despite surgical removal of primary tumors, however,
relapse at local or distant sites occurs in a subset of patients,
probably due to undetectable micrometastases at the time of
diagnosis [2,3].
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Cancer therapies directed at specific molecular targets in sig-
naling pathways of cancer cells, such as tamoxifen, aromatase
inhibitors and trastuzumab (Herceptin), have been proven to
be useful for treatment of advanced breast cancer [4].
Tamoxifen and aromatase inhibitors suppress the estrogen-
related signaling pathway and trastuzumab is the first
approved monoclonal antibody for blocking the human epider-
mal growth factor 2 (HER-2/ErbB-2) signaling pathway [4,5].
Patients with tumors that express estrogen or HER-2 recep-
tors can benefit from either of these therapies and are
expected to have a better quality of life and prognosis. How-
ever, increased risk of endometrial cancer with long-term
tamoxifen administration and of bone fracture due to oste-
oporosis in postmenopausal women undergoing aromatase
inhibitor therapy are recognized side effects [6,7]. Due to the
emergence of these side effects and also because of drug
resistance, it is necessary to search for novel molecular targets
for drugs on the basis of well-characterized mechanisms of
action.
Toward the goal of identifying good molecular targets for drug
development, we analyzed the detailed expression profiles of
81 breast tumors, representing 23,040 genes, using a combi-
nation of laser-microbeam microdissection and cDNA microar-
ray analysis [8]. After comparing the expression profiles of
these breast cancers with those of various normal human tis-
sues [9], we focused on a gene termed maternal embryonic
leucine zipper kinase (MELK) that was significantly overex-
pressed in the great majority of breast cancer cases examined.
In this study, we report evidence indicating that MELK func-
tions as a cancer-specific protein kinase, and that down-regu-
lation of MELK results in growth suppression of breast cancer
cells. In addition, we demonstrate that MELK physically inter-
acts and phosphorylates a long isoform of Bcl-G (Bcl-GL), a
pro-apoptotic member of the Bcl-2 family. Our findings sug-
gest that the kinase activity of MELK is likely to affect mammary
carcinogenesis through inhibition of the pro-apoptotic function
of Bcl-GL. We propose that MELK kinase activity could be a
promising molecular target for the treatment of breast cancer.
Materials and methods
Cancer cell lines and clinical samples
Human breast cancer cell lines HBL100, HCC1937, MCF-7,
MDA-MB-231, MDA-MB-435S, SKBR3, T47D, YMB1, BSY-
1 and BT-20, human cervical adenocarcinoma cell line, HeLa,
and monkey kidney cells transformed with SV40 T-antigen,
COS7 cells, were purchased from the American Type Culture
Collection (ATCC, Rockville, MD, USA). Human mammary epi-
thelial cells (HMECs) were purchased from Cambrex Bio Sci-
ence Walkersville, Inc. (Walkersville, MD, USA). HBC4 and
HBC5 cells lines were kind gifts from Dr Yamori of the Division
of Molecular Pharmacology, Cancer Chemotherapy Center,
Japanese Foundation for Cancer Research. All cells were cul-
tured under their respective depositor's recommendations:
RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) for HBC4,
HBC5, HCC1937, SKBR3, T47D, YMB1 and BSY-1 (with 2
mM L-glutamine); Dulbecco's modified Eagle's medium (Invit-
rogen, Carlsbad, CA, USA) for HBL100, BT-20 and COS7;
EMEM (Sigma-Aldrich) with 0.1 mM essential amino acid
(Roche, Basel, Switzerland), 1 mM sodium pyruvate (Roche),
0.01 mg/ml insulin (Sigma-Aldrich) for MCF-7; EMEM (Sigma-
Aldrich) for HeLa; L-15 (Roche) for MDA-MB-231 and MDA-
MB-435S; MEGM (Cambrex Bio Science) for HMECs. Each
medium was supplemented with 10% fetal bovine serum
(Cansera International, Ontario, Canada) and 1% antibiotic/
antimycotic solution (Sigma-Aldrich). MDA-MB-231 and
MDA-MB-435S cells were maintained at 37°C in humidified
air without CO2. Other cell lines were maintained at 37°C in
humidified air with 5% CO2. Tissue samples from surgically
resected breast cancers, and their corresponding clinical
information, were obtained from the Department of Breast Sur-
gery, Cancer Institute Hospital, Tokyo, after obtaining written
informed consent.
Semi-quantitative RT-PCR analysis
Total RNAs were extracted from each microdissected breast
cancer clinical sample and from microdissected normal ductal
cells, and polyA(+) RNAs were isolated from normal mammary
gland, lung, heart, liver, and kidney (Takara Clontech, Kyoto,
Japan). Subsequently, T7-based amplification and reverse
transcription were carried out as described previously [10].
We prepared appropriate dilutions of each single-stranded
cDNA for subsequent PCR using the glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) gene as a quantitative con-
trol. The PCR primer sequences were: 5'-
GCTGCAAGGTATAATTGATGGA-3' and 5'-CAGTAACAT-
AATGACAGATGGGC-3' for MELK; 5'-CGACCACTTTGT-
CAAGCTCA-3' and 5'-GGTTGAGCACAGGGTACTTTATT-
3' for GAPDH.
Northern blot analysis
Total RNAs were extracted from breast cancer cell lines using
the RNeasy kit (Qiagen, Valencia, CA, USA) according to the
manufacturer's instructions. After treatment with DNase I (Nip-
pon Gene, Osaka, Japan), mRNA was isolated with a mRNA
purification kit (GE Healthcare, Buckinghamshire, United King-
dom) following the manufacturer's instructions. One micro-
gram of each mRNA, along with polyA(+) RNAs isolated from
normal mammary gland, lung, heart, liver, kidney and brain
(Takara Clontech), were separated on 1% denaturing agarose
gels and transferred to nylon membranes (breast cancer
Northern blots). Breast cancer Northern blots and human mul-
tiple-tissue Northern blots (Takara Clontech) were hybridized
with [α32P]-dCTP-labeled PCR products of MELK cDNA pre-
pared by RT-PCR (see below). Pre-hybridization, hybridization
and washing were performed according to the supplier's rec-
ommendations. The blots were autoradiographed with intensi-
fying screens at -80°C for 12 days. A probe cDNA (542 base-
pairs (bp)) for the sequence in the 3' untranslated region ofAvailable online http://breast-cancer-research.com/content/9/1/R17
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MELK cDNA (GenBank accession number NM_014791) was
prepared by PCR using the primer set 5'-TTATCACTGTGCT-
CACCAGGAG-3' and 5'-CAGTAACATAATGACAG
ATGGGC-3' and were radioactively labeled using the meg-
aprime DNA labeling system (GE Healthcare).
cDNA library screening
We constructed a cDNA library using polyA(+) RNA obtained
from T47D breast cancer cells and the Superscript™ plasmid
system coupled with Gateway™ technology for cDNA synthe-
sis and a cloning kit (Invitrogen). We screened 3 × 106 inde-
pendent clones from this library with a cDNA probe
corresponding to nucleotides 1,251 to 2,094 (843 bp) of the
MELK  cDNA sequence (GenBank accession number
NM_014791).
In vitro translation assay
Three variants of MELK (V1, V2 and V3) that were cloned into
the pSPORT-1 expression vector were used as templates for
transcription/translation experiments in vitro. The plasmids (1
μg) were transcribed and translated using a TNT Coupled
Reticulocyte Lysate system (Promega, Madison, WI, USA) in
the presence of ε-labeled biotinylated lysine-tRNA according
to the manufacturer's instructions. Proteins were electro-
phoresed by SDS-PAGE with a 5% to 20% gradient. After
electroblotting, the biotinylated proteins were visualized by
binding streptavidin-horseradish peroxidase followed by
chemiluminescent detection (GE Healthcare).
Plasmid construction
To construct MELK  expression vectors, the entire coding
sequences were amplified by PCR using KOD-Plus DNA
polymerase (Toyobo, Osaka, Japan) and cloned into the EcoRI
and XhoI sites of the pCAGGSnHC expression vector in frame
with the HA (hemagglutinin)-tag at the carboxyl terminus. The
primer set used for PCR reactions with wild-type MELK-V1
was: forward, 5'-CGGAATTCACTATGAAAGATTATG
ATGAAC-3' (underlining indicates the EcoRI site); reverse, 5'-
AAACTCGAGTACCTTGCAGCTAGATAGGAT-3' (underlin-
ing indicates the XhoI site). Kinase-dead mutant MELK
(D150A) was generated with a QuikcChange Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA, USA) using the fol-
lowing primers; forward, 5'-CATAAATTAAAGCTGATT-
GCCTTTGGTCTCTGTGCAAAACC-3'; reverse: 5'-
GGTTTTGCACAGAGACCAAAGGCAATCAGCTTTAATT-
TATG-3'.
For construction of the Bcl-GL expression vectors, the corre-
sponding open reading frame was generated by RT-PCR
using human testis mRNA as a template and the following set
of primers (underlining of forward and reverse primers indi-
cates  NotI and XhoI sites, respectively): forward, 5'-ATAA-
GAATGCGGCCGCGATGTGTAGCACCAGTGG-3' for full-
length  Bcl-GL  (FL); reverse, 5'-CCGCTCGAGTTACTAT-
CAGTCTACTTCTTCATGTG-3' for full-length Bcl-GL  (FL);
forward 5'-ATAAGAATGCGGCCGCGATCCCCCTAGAT-
GATG-3' for N-1; forward 5'-ATAAGAATGCGGCCGCGT-
GGCCTTGCAGAAATTC-3' for N-2; forward 5'-
ATAAGAATGCGGCCGCGGAATACCAAGATTCGC-3' for
N-3; forward 5'-ATAAGAATGCGGCCGCGCAGGCAG-
GAGGCTTC-3' for N-4; reverse 5'-CCGCTCGAGTTACTAT-
CAGAAGTTCTCTTTCAGGT-3' for C-1; reverse 5'-
CCGCTCGAGTTACTATCATCTGGGGTCCACACCCA-3'
for C-2; reverse 5'-CCGCTCGAGTTACTATCACAGCT-
CAACAATTTTGG-3' for C-3. The reverse primer of the FL
construct was commonly used for N-1, N-2, N-3 and N-4 con-
structs, and the forward primer of it was commonly used for C-
1, C-2 and C-3 constructs. These amplified DNAs were
cloned into NotI and XhoI sites of the pCAGGSn3FH vector in
frame with Flag-tag at the amino-terminal site. DNA sequences
of all constructs were confirmed by DNA sequencing
(ABI3700, PE Applied Biosystems, Foster, CA, USA).
Gene-knockdown of MELK by siRNA
We established a vector-based RNA interference (RNAi)
expression system using a psiH1BX3.0 small interfering
(si)RNA expression vector as described previously [11].
siRNA expression vectors against MELK  (psiH1BX-MELK)
and scramble control (SC; the gene coding for 5S and 16S
rRNAs in the chloroplast of Euglena gracilis; psiH1BX-SC)
were prepared by cloning of double-stranded oligonucleotides
into the BbsI site of the psiH1BX3.0 vector. The target
sequence of synthetic oligonucleotides for siRNA were: si-#1,
5'-TCCCACTTGCCTGCCATATCCTTTTCAAGAGAAAG-
GATATGGCAGGCAAGT-3' and 5'-
AAAAACTTGCCTGCCATATCCTTTCTCTTGAAAAGGA-
TATGGCAGGCAAGT-3', si-#2, 5'-
TCCCCTATCCTGTTGAGTGGCAATTCAAGAGATT-
GCCACTCAACAGGATAG-3' and 5'-
AAAACTATCCTGTTGAGTGGCAATCTCTTGAATT-
GCCACTCAACAGGATAG-3', si-#3, 5'-
TCCCGACATCCTATCTAGCTGCATTCAAGAGAT-
GCAGCTAGATAGGATGTC-3' and 5'-
AAAAGACATCCTATCTAGCTGCATCTCTTGAAT-
GCAGCTAGATAGGATGTC-3', si-#4, 5'-
TCCCAGTTCATTGGAACTACCAATTCAAGAGATTGG-
TAGTTCCAATGAACT-3' and 5'-
AAAAAGTTCATTGGAACTACCAATCTCTTGAATTGG-
TAGTTCCAATGAACT-3'. SC, 5'-
TCCCGCGCGCTTTGTAGGATTCGTTCAAGAGAC-
GAATCCTACAAAGCGCGC-3' and 5'-
AAAAGCGCGCTTTGTAGGATTCGTCTCTTGAAC-
GAATCCTACAAAGCGCGC-3'. Underlining indicates
siRNA-targeting sequences designed from MELK  mRNA
(GenBank accession number NM_014791). All constructs
were also confirmed by DNA sequencing.
Human breast cancer cells lines T47D and MCF-7 were
plated in 15 cm dishes (4 × 106 cells/dish), and transfected
with 16 μg of psiH1BX-MELK (si-#1, si-#2, si-#3 and si-#4)Breast Cancer Research    Vol 9 No 1    Lin et al.
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and psiH1BX-SC (SC; negative control) siRNA plasmids
using the FuGENE6 transfection reagent (Roche) according
to the supplier's recommendations. At 24 hours after transfec-
tion, cells were re-seeded for the following experiments at the
densities given: 1 × 106 cells/10 cm dish for semi-quantitative
RT-PCR and western blot analyses; 3 × 106 cells/10 cm dish
for colony formation assay and 5 × 105 cells/well for MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay. We selected T47D or MCF7 cells transfected with
MELK-siRNAs in medium containing 0.7 mg/ml or 0.6 g/ml
neomycin (geneticine; Invitrogen), respectively. Four days after
neomycin selection, 0.5 μg of total RNA extracted from these
cells was reverse-transcribed into cDNA using Superscript II
(Invitrogen) to examine the knockdown effect of siRNAs by
semi-quantitative RT-PCR using specific primer sets for MELK
and β2MG (encoding beta-2-microglobulin). Cells were also
harvested four days after neomycin selection for western blot
analysis using anti-MELK antibody (Cell signaling technology,
Boston, MA, USA). The specific primer sets for RT-PCR were:
5'-TTATCACTGTGCTCACCAGGAG-3' and 5'-CAGTAA-
CATAAT GACAGATGGGC-3' for MELK; 5'-TTAGCTGT-
GCTCGCGCTACT-3' and 5'-
TCACATGGTTCACACGGCAG-3' for β2MG as a quantita-
tive control. Transfectants expressing siRNA were grown for 3
weeks in selective media containing neomycin, then fixed with
4% paraformaldehyde for 15 minutes before staining with
Giemsa's solution (Merck, Whitehouse Station, NJ, USA) to
assess colony number. To quantify cell viability, MTT assays
were performed at seven days after selection with Cell Count-
ing Kit-8 (Wako, Osaka, Japan) according to the manufac-
ture's protocols. Absorbance at 570 nm was measured with a
Microplate Reader 550 (Bio-Rad, Hercules, CA, USA). These
experiments were performed in triplicate.
Generation and purification of His-tagged recombinant 
MELK
The entire coding sequences of wild-type MELK (WT-MELK)
and kinase-dead MELK (D150A-MELK; asparate changed to
alanine at the 150th residue in the kinase subdomain VII,
which is considered as the ATP binding site [12]) were sub-
cloned into the pET21a vector (Merck Novagen, Darmstadt,
Germany). The WT-MELK and D150A-MELK recombinant
proteins were expressed in Escherichia coli strain BL21
codon-plus (DE3) RIL competent cells (Stratagene), and cul-
tured in TBG-M9 medium (1% tryptone, 0.5% NaCL, 0.5%
glucose, 1 mM MgSO4, 0.1% NH4CI, 0.3% KH2PO4, 0.6%
Na2HPO4). After induction with 0.5 μM isopropyl-b-D-thioga-
lactopyranoside (IPTG) at 25°C for 5 hours, the bacteria pellet
was suspended with lysis buffer, and was purified with Ni-NTA
superflow (Qiagen) under nondenaturing conditions accord-
ing to the supplier's instructions. The entire coding sequence
of BCL-GL was also subcloned into the pGEX-6P-1 vector
(GE Healthcare). The glutathione S-transferase (GST)-Bcl-GL
recombinant protein was expressed in Escherichia coli strain
BL21 codon-plus RIL competent cells (Stratagene). Purifica-
tion of the recombinant proteins was performed using Glutath-
ione Sepharose 4B beads (GE Healthcare) under
nondenaturing conditions according to the supplier's instruc-
tions. For confirmation of direct binding of BCL-GL and MELK,
we removed GST from GST-fused BCL-GL protein using Pre-
Scission protease (GE Healthcare) according to the supplier's
instructions.
Protein pull down assay
HBC4 cells were lysed with lysis buffer (40 mM Tris-HCL (pH
7.5), 1% Trition X-100, 2.5 mM EDTA, 15 mM dithiothreitol
(DTT)) including 0.1% protease inhibitor cocktail III (Calbio-
chem, San Diego, CA, USA) as previously described [13] with
a minor modification. We incubated 7.5 mg of cell lysates with
0.5 μM of WT-MELK or D150A-MELK recombinant proteins
pre-immobilized on Ni-NTA agarose beads in reaction buffer
containing 50 mM Tris-HCL (pH 7.5), 50 μM ATP, 10 mM
MgCL2, 25 mM NaCL and 1 mM DTT at 30°C for 5 minutes.
The protein-bound beads were washed three times with lysis
buffer, and then eluted with SDS sample buffer. The proteins
were separated by SDS-PAGE using a 4% to 12% gradient
Bis-Tris gel (Invitrogen), and stained with Silver Stain DAIICHI
(Daiichi Pure Chemicals, Tokyo, Japan). An approximately 30
kDa band, which was seen in pulled-down cell lysates with
WT-MELK added but not in those with D150A-MELK added,
was extracted. Its peptide sequence was determined by
MALDI-TOF mass spectrometry.
Western blot analysis
To detect the endogenous MELK and Bcl-GL  proteins in
breast cancer cell lines (BT-20, HBC4, HBC5, HBL100,
MCF-7, MDA-MB-231, SKBR3 and T47D) and HMECs, these
cells were lysed in lysis buffer (50 mM Tris-HCL pH 8.0, 150
mM NaCL, 0.5% NP-40) including 0.1% protease inhibitor
cocktail III (Calbiochem). After homogenization, the cell lysates
were incubated on ice for 30 minutes and centrifuged at
14,000 rpm for 15 minutes to separate only supernatant from
cell debris. The amount of total protein was estimated by pro-
tein assay kit (Bio-Rad), and the proteins were then mixed with
SDS sample buffer and boiled for 3 minutes before loading
into a 10% to 20% gradient SDS-PAGE gel (Bio-Rad). After
electrophoresis, the proteins were transferred onto nitrocellu-
lose membrane (GE Healthcare). Membranes were blocked
by 4% BlockAce (Dainippon Pharmaceutical Co., Ltd, Osaka,
Japan), and incubated with anti-MELK polyclonal or anti-Bcl-
GL polyclonal antibodies (Abcam, Cambridge, MA, USA). β-
Actin served as a loading control. Finally, the membranes were
incubated with horseradish peroxidase (HRP) conjugated sec-
ondary antibody and protein bands were visualized by
enhanced chemiluminescence (ECL) detection reagents (GE
Healthcare).
Co-immunoprecipitation assay
HeLa cells were transiently co-transfected for 48 hours with 8
μg of plasmid constructs encoding Flag-tagged full-lengthAvailable online http://breast-cancer-research.com/content/9/1/R17
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Bcl-GL or a series of Flag-tagged partial Bcl-GL proteins (FL,
N-1, N-2, N-3, N-4, C-1, C-2 and C-3) as well as the same
amount of plasmid encoding HA-tagged WT-MELK, using the
FuGENE6 transfection reagent (Roche). Cells were lysed with
lysis buffer as described above. The lysates were pre-cleaned
with normal mouse IgG (1.2 μg) and rec-Protein G Sepharose
4B (Zymed, San Francisco, CA, USA) at 4°C for 30 minutes.
Subsequently, the lysate was incubated with anti-Flag agarose
M2 gel (Sigma-Aldrich) at 4°C for 12 hours. After washing
three times with lysis buffer, proteins on beads were eluted
with SDS sample buffer.
In vitro binding assay
The His-tagged MELK recombinant protein (10 μg) was immu-
noprecipitated with anti-6XHis-tag monoclonal antibody (2 μg;
Takara Clontech) in 500 μl of coupling buffer (50 mM Tris, 75
mM NaCL, 10 mM MgCL2, 1 mM DTT, and complete EDTA-
free protease inhibitors; Roche) for 3 hours at 4°C. Subse-
quently, 30 μl of protein G Sepharose (Zymed) was added,
and the incubation was further continued for 45 minutes. The
immune complexes were washed 3 times with 1 ml of coupling
buffer, and resuspended with 500 μl of binding buffer (50 mM
Tris, 75 mM NaCL, 10 mM MgCL2, 1 mM DTT, 2% bovine
serum albumin, 100 μM ATP and complete EDTA-free pro-
tease inhibitors; Roche) containing 5 μg of Bcl-GL recom-
binant protein. After incubation for 30 minutes at 4°C for
binding, the samples were washed 5 times with washing
buffer (50 mM Tris-CL, 75 mM NaCL, 10 mM MgCL2, 1 mM
DTT, 0.01% Triton-X100 and complete EDTA-free protease
inhibitors; Roche). The precipitates were then eluted with SDS
sample buffer by boiling for 3 minutes and analyzed by western
blot with anti-Bcl-GL antibody.
Immunocomplex kinase assay
To use the long isoform Bcl-GL recombinant protein as a sub-
strate for kinase assay, a set of Flag-tagged Bcl-GL (FL, N-1,
N-2 N-3 and N-4) expression vectors was transfected into
HeLa cells, and the proteins were immunoprecipitated with
Flag-conjugated agarose M2 gel (Sigma-Aldrich) at 4°C for 1
hour. These immunoprecipitates were washed five times with
lysis buffer containing 50 mM Tris-HCL (pH 7.5), 150 mM
NaCL, 1% NP-40 and 0.1% protease inhibitor cocktail III (Cal-
biochem). Aliquots (20 μl) of immunoprecipitates were sub-
jected to immunoblotting using rabbit anti-Flag antibody
(Sigma-Aldrich) to check the success of the immunoprecipita-
tion experiments. His-tagged MELK recombinant proteins (0.5
μM WT-MELK and D150A-MELK) were reacted for 30 min-
utes at 30°C with aliquots (20 μl) of immunoprecipitates of
Flag-tagged Bcl-GL (FL, N-1 N-2, N-3 and N-4) as substrates
in 50 μl of kinase buffer containing 30 mM Tris-HCL (pH 7.5),
0.1 mM EGTA, 10 mM DTT, 40 mM NaF, 40 mM sodium β-
glycerophosphate (Sigma-Aldrich), 50 μM cold-ATP, 10 Ci of
[γ-32P] ATP (GE Healthcare) and 10 mM MgCL2. The reaction
was terminated by addition of SDS sample buffer and boiled
for 3 minutes prior to 10% SDS-PAGE. The gel was then dried
and autoradiographed with intensifying screens at room tem-
perature overnight.
TUNEL assay for apoptosis
COS7 cells (1 × 106) were co-transfected with 8 μg each of
Flag-tagged pCAGGSn3FH vectors (Flag-Bcl-GL and Flag-
Mock) and HA-tagged pCAGGSnHC vectors (HA-WT-MELK,
HA-D150A-MELK and HA-Mock) using the FuGENE 6 trans-
fection reagent (Roche) according to the supplier's protocol.
At 24 hours post-transfection, cells were harvested by trypsini-
zation and washed with phosphate buffered saline without
CaCL2 and MgCL2 (PBS(-)). An aliquot of cells (300 μl) was
immobilized on the microslide glass (Matsunami Glass, Osaka,
Japan) and subjected to a TUNEL assay using an In situ Cell
Death Detection Kit, Fluorescein (Roche) according to the
supplier's instructions. The apoptotic cells were observed with
a TCS SP2 AOBS microscope (Leica, Tokyo, Japan). Experi-
ments were carried out in triplicate independently.
Flow cytometry analysis for apoptosis
COS7 cells (1 × 106) were co-transfected with 8 μg each of
Flag-tagged pCAGGSn3FH vectors (Flag-Bcl-GL and Flag-
Mock) and HA-tagged pCAGGSnHC vectors (HA-WT-MELK,
HA-D150A-MELK and HA-Mock) using the FuGENE 6 trans-
fection reagent (Roche). For FACS analysis, the cells were
harvested by trypsinization and fixed with 70% ethanol at room
temperature for 30 minutes. After centrifuging to remove the
ethanol, the cells were treated with 0.5 ml of PBS(-) containing
1 mg/ml of RNase I (Sigma-Aldrich) for 30 minutes followed by
staining in 1 ml of PBS(-) containing 20 mg/ml of propidium
iodide (Sigma-Aldrich) for 30 minutes. The cells selected from
at least 10,000 ungated cells were analyzed for DNA content
by flow cytometry (FACS calibur; Becton Dickinson, San
Diego, CA, USA). The data were analyzed using CELLQuest
software (FACS calibur; Becton Dickinson). Assays were
done in triplicate independently.
Statistical analysis
Statistical significance was determined by Student's t-test
using Statview 5.0 software (SAS Institute, Cary, NC, USA). A
difference of P  < 0.05 was considered to be statistically
significant.
Results
Up-regulation of MELK in breast cancer
We previously reported the genome-wide expression profile
analysis of 81 clinical breast cancers, representing 23,040
genes, by means of cDNA microarray analysis in combination
with enrichment of cancer cells with a laser microbeam micro-
dissection system [8]. The MELK gene (GenBank accession
number NM_014791) was found to be one of the genes trans-
activated at a very high level in the great majority of the breast
cancers examined. The subsequent semi-quantitative RT-PCR
analysis of the transcript confirmed the elevated expression ofBreast Cancer Research    Vol 9 No 1    Lin et al.
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MELK in 11 of 12 clinical breast cancer specimens (Figure
1a).
To further examine the expression pattern of this gene in
breast cancer cell lines and normal tissues, we performed
Northern blot analyses with mRNAs from multiple human tis-
sues and breast cancer cell lines using a cDNA fragment cor-
responding to the 3' untranslated region of the MELK gene as
a probe. The results showed that an approximately 2.7 kb
band was most highly expressed in testis, and weakly
expressed in thymus and small intestine (Figure 1b). Interest-
ingly, Northern blot analyses of breast cancer cell lines using
the same probe showed that 2.4 to 2.7 kb bands were signif-
icantly over-expressed in breast cancer cells but were not
expressed in vital organs (Figure 1c), indicating that some can-
cer specific transcripts are present over this range.
To characterize the variants specifically transcribed in breast
cancer cells, we screened a cDNA library of breast cancer
cells. Subsequent cDNA sequencing analysis identified three
different transcriptional variants, designated V1 (2,501 bp;
NM_014791), V2 (2,368 bp; AB183427) and V3 (2,251 bp;
Figure 1
Expression and distribution of MELK in human normal tissues and breast cancer cell lines Expression and distribution of MELK in human normal tissues and breast cancer cell lines. (a) Expression of MELK in 12 breast cancer specimens 
(case number; 42, 102, 247, 252, 302, 473, 478, 502, 552, 646, 769 and 779) by semi-quantitative RT-PCR. GAPDH served as a quantitative 
internal control. (b) Multiple tissue Northern blot analysis demonstrated that an approximately 2.7 kb MELK transcript was detected in the testis, thy-
mus and small intestine. PBL, peripheral blood leukocytes. (c) Breast cancer cell line Northern blot analysis revealed that approximately 2.4 to 2.7 kb 
MELK variants were specifically expressed in breast cancer cell lines, but not in normal vital organs. (d) Schematic representation of three variant 
transcripts identified by cDNA library screening (see Materials and methods). White boxes indicate a coding region and black boxes indicate a non-
coding region. Black and grey triangles indicate initiation codons, and white triangles indicate stop codons. Exon numbers are shown above each 
box. (e) In vitro translation assay of each variant isolated from cDNA library screening. The number within parentheses represents the predicted 
molecular weight (kDa) of each variant protein. (f) Expression of MELK proteins in eight breast cancer cell lines as well as human mammary epithelial 
cells (HMECs) shown by western blot analysis with an anti-MELK antibody. β-Actin served as a control. (g) Schematic representation of the V1, V2 
and V3 forms of MELK. The shaded boxes indicate the catalytic domain (amino acids 11 to 263 of the V1 protein). The KA1 domain is the kinase-
associated domain in the carboxy-terminal region.Available online http://breast-cancer-research.com/content/9/1/R17
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AB183428). These three different transcriptional variants con-
sist of 18, 17 and 16 exons, respectively. The V2 variant lacks
exon 3 (86 bp) and the V3 variant lacks exon 3 (86 bp) and
exon 4 (117 bp) as a result of alternative splicing (Figure 1d).
The V2 and V3 variants contain early stop codons (TGA) in
exon 4 and exon 5, respectively, if they are translated from the
same first ATG codon of the V1 variant. However, if they are
translated from a second ATG codon located downstream of
the first ATG codon of the V1 variant, the V2 and V3 variant
proteins are thought to produce 618 and 581 amino acid pep-
tides, respectively. Thus, to examine both possibilities, we car-
ried out an in vitro translation assay and found that the V1, V2
and V3 proteins were 75, 71 and 66 kDa, respectively, indicat-
ing that the V2 and V3 proteins were translated from the sec-
ond ATG codon (Figure 1e).
Subsequently, we examined MELK expression in breast can-
cer cell lines by western blot analysis with anti-MELK polyclo-
nal antibodies. The results indicate that the V1 protein is
dominantly overexpressed in breast cancer cells compared
with the V2 and V3 proteins (Figure 1f). Furthermore, although
all of the three variant proteins possess the KA1 domain in
their carboxyl terminus, the V2 and V3 proteins lack the amino-
terminal portion, which corresponds to the first 48 amino acids
of the V1 protein and is considered to be the catalytic kinase
domain (Figure 1g). Although we can not rule out the possibil-
ity that the V2 and V3 variants have some functional role in car-
cinogenesis, for example, dominant-negative functions, in this
study we focus on the kinase activity of the V1 transcript due
to its predominant expression in cancer cells.
Growth-inhibitory effects of siRNA against MELK
To assess a possible role of MELK in mammary carcinogene-
sis, we knocked down the expression of endogenous MELK in
the breast cancer cell lines T47D and MCF7 (Figure 2a,b), in
which MELK was overexpressed at a high level, by means of
the mammalian vector-based RNAi technique (see Materials
and methods). We examined expression levels of MELK by
semi-quantitative RT-PCR and western blot analyses, and
found that the MELK-siRNAs si-#3 and si-#4 significantly
reduced its expression at the transcriptional and protein levels
compared with scramble-siRNA (SC), si-#1 and si-#2 (Figure
2). Colony formation and MTT assays revealed that both si-#3
and si-#4 significantlysuppressed growth of T47D and MCF7
cells (MTT assay in T47D, P = 0.0003, P = 0.0013; in MCF-
7, P = 0.0001, P = 0.0001; unpaired t-test), in concordance
with the results showing the knockdown effect of this gene.
These results suggest that MELK has a critical role in the
growth of breast cancer cells.
Identification of Bcl-GL as a MELK-interacting protein
To investigate the biological functions of MELK in breast can-
cer cells, we searched for substrates of MELK in cancer cells
by in vitro protein pull-down assays using wild-type MELK
(WT-MELK) and kinase-dead MELK (D150A-MELK) recom-
binant proteins. Comparison of silver staining of SDS-PAGE
gels containing the pulled-down proteins identified an approx-
imately 30 kDa protein in the lane corresponding to proteins
pulled-down with WT-MELK but not in that corresponding to
proteins pulled-down with D150A-MELK (Figure 3a). MALDI-
TOF analysis showed this 30 kDa protein to be Bcl-G, a mem-
ber of the Bcl-2 protein family [14]. According to NCBI data-
base, Bcl-G has three alternative splicing isoforms, termed
Bcl-G short isoform (Bcl-GS), median isoform (Bcl-Gm) and
long isoform (Bcl-GL), and encoding 252, 276 and 327 amino
acid peptides, respectively.
We first examined the expression patterns of these Bcl-G iso-
forms at the transcriptional level in breast cancer cell lines by
semi-quantitative RT-PCR, and found that Bcl-GS and Bcl-GL
were expressed in all breast cancer cells examined, whereas
the Bcl-Gm transcript was not detected at all (data not shown).
Furthermore, we examined expression of endogenous Bcl-GL
in breast cancer cell lines at the protein level by western blot
analysis using an anti-Bcl-GL  antibody and detected an
approximately 30 kDa endogenous Bcl-GL, corresponding to
the size identified by protein pull-down experiment, in all the
breast cancer cell lines examined (Figure 3b). Therefore, we
focused on Bcl-GL  as a candidate interacting protein for
MELK.
To validate an interaction between WT-MELK and Bcl-GL, we
constructed plasmids designed to express HA-tagged WT-
MELK (HA-WT-MELK) and Flag-tagged Bcl-GL (Flag-Bcl-GL).
These plasmids were co-transfected into HeLa cells and the
proteins immunoprecipitated with anti-Flag antibody. Immuno-
blotting of the precipitates using anti-HA antibodies indicated
that Flag-Bcl-GL was co-precipitated with HA-WT-MELK (Fig-
ure 3c). Furthermore, we demonstrated that His-tagged WT-
MELK could pull-down with Bcl-GL but His-tagged D150A-
MELK could not, indicating that, in vitro, Bcl-GL interacts
directly with WT-MELK but not with D150A-MELK (Figure 3d).
To further determine which segment of Bcl-GL can interact
with WT-MELK, we performed co-immunoprecipitation analy-
ses using HA-WT-MELK and partial Bcl-GL proteins tagged
with Flag (Figure 3e). After co-transfection of plasmid clones
into HeLa cells, we performed immunoprecipitation with an
anti-Flag antibody, and then immunoblotting with an anti-HA
antibody. We found that the N-1 construct (amino acids 12 to
327) as well as a full-length Bcl-GL (FL) bound to WT-MELK,
whereas N-2 (amino acids 72 to 324), N-3 (amino acids 121
to 327) or N-4 (amino acids 171 to 327) did not (Figure 3f).
Concordantly, all of the partial products that contained the
amino-terminal portion of Bcl-GL – C-1 (amino acids 1 to 305),
C-2 (amino acids 1 to 295), and C-3 (amino acids 1 to 215)
bound to WT-MELK (Figure 3f). These results suggest that the
region corresponding to amino acids 12 to 71 of Bcl-GL is
likely to interact with WT-MELK.Breast Cancer Research    Vol 9 No 1    Lin et al.
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MELK phosphorylates Bcl-GL
To examine whether the Bcl-GL protein is a substrate of MELK
kinase activity, we performed an immune complex kinase
assay. We first confirmed the exogenous expression of Flag-
tagged Bcl-GL (Flag-Bcl-GL) by western blot analysis (Figure
3f). As shown in Figure 4a, WT-MELK could phosphorylate
Bcl-GL, but D150A-MELK could not (single arrowhead). In
addition, autophosphorylation of an approximately 75 kDa pro-
tein of MELK was observed (Figure 4a; double arrowheads).
Furthermore, we also confirmed that WT-MELK could phos-
phorylate GST-Bcl-GL but D150A-MELK could not (Figure
4b), indicating MELK can directly phosphorylate Bcl-GL.
These findings suggest that Bcl-GL is a potential substrate for
MELK.
We subsequently examined WT-MELK kinase activity on vari-
ous partial amino-terminal Bcl-GL products (Figure 3e). First,
we confirmed the amount of immunoprecipitated protein cor-
responding to partial Bcl-GL (N-1, N-2, N-3 and N-4) as well as
to full-length Bcl-GL (FL) by western blot analysis (Figure 3f),
and then examined the extent of their phosphorylation (Figure
4c). The MELK recombinant protein phosphorylated N-1 as
Figure 2
Effect of knockdown of MELK by small-interfering RNA (siRNA) on cell viability and proliferation Effect of knockdown of MELK by small-interfering RNA (siRNA) on cell viability and proliferation. Four psiH1 promoter-based siRNA constructs (si-
#1, si-#2, si-#3 and si-#4) were introduced into (a) T47D and (b) MCF-7 cell lines. SC refers to scramble used as a control for siRNA experiments. 
Gene silencing was evaluated by semi-quantitative RT-PCR and western blot analyses at four and five days after neomycin selection, respectively. 
β2-microglobulin (β2MG) was used as a control for normalization of semi-quantitative RT-PCR, and β-actin was used as a control in western blot 
analysis. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed to evaluate cell viability at 10 days after neomy-
cin selection, and graphed after standardization using the scramble control (SC) as 1.0 (T47D, P = 0.0003, P = 0.0013; MCF-7, P = 0.0001, P = 
0.0001; unpaired t-test). Colony formation assays were carried out three weeks after neomycin selection (see Materials and methods). Two siRNA 
constructs (si-#3 and -#4) showed significant knockdown effects against internal MELK expression and inhibited cell growth in both T47D (a) and 
MCF-7 (b) cell lines. Values represent the average from triplicate experiments. Error bars indicate standard deviation.Available online http://breast-cancer-research.com/content/9/1/R17
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well as full-length Bcl-GL, whereas it could not phosphorylate
N-2, N-3 or N-4 proteins, corresponding with their inability to
interact.
MELK involvement in the apoptotic pathway through Bcl-GL
Because MELK can physically interact with and phosphorylate
Bcl-GL (Figures 3d and 4a), we hypothesized that it might be
involved in the apoptosis cascade through the Bcl-GL-related
pathway. To investigate this hypothesis, we transiently co-
transfected two plasmid clones designed to express HA-
tagged MELK (WT or D150A) and Flag-tagged Bcl-GL into
COS7 cells, and then performed a TUNEL assay and FACS
analysis to measure the proportions of apoptotic cells (see
Material and methods). We first confirmed the exogenous
expression of MELK and Bcl-GL in COS7 cells by western blot
analysis (Figure 5a). As indicated in Figure 5b,c, the overex-
Figure 3
Identification of Bcl-GL as an interacting protein for MELK Identification of Bcl-GL as an interacting protein for MELK. (a) Silver staining of SDS-PAGE gels that contained the pulled-down cell lysates. The 
enlarged area covering Bcl-G shows the differential interaction between it and wild-type MELK (WT-MELK) and kinase-dead MELK (D150A-MELK). 
(b) Expression of Bcl-GL in eight breast cancer cell lines as well as human mammary epithelial cells (HMECs) by western blot analysis with an anti-
Bcl-GL antibody. β-Actin was used as a control. (c) Interaction of MELK with Bcl-GL. Extracts from HeLa-cells transfected with HA (hemagglutinin)-
tagged WT-MELK (HA-WT-MELK) or Flag-tagged Bcl-GL (Flag-Bcl-GL), or a combination of these, were harvested 36 hours after transfection. The 
cell lysates were immunoprecipitated with anti-Flag M2 antibody. Precipitated proteins were separated by SDS-PAGE and western blotting analysis 
was performed with an anti-HA antibody. (d) Direct interaction of the MELK and Bcl-GL proteins. The upper panel indicates the amount of input of 
WT-MELK and D150A-MELK. His-tagged WT-MELK bound to Bcl-GL, but His-tagged D150A-MELK did not. (e) Schematic representation of the 
amino- and carboxy-terminal deletion constructs of Bcl-GL. The C-1 and C-2 constructs have the BH2 domain deleted, and the C-3 construct has 
both the BH2 and BH3 domains deleted. (f) Determination of the WT-MELK binding regions of Bcl-GL by immunoprecipitation. The HA-tagged WT-
MELK and various peptide sequences of Flag-tagged Bcl-GL (Figure 3e) were pulled down by immunoprecipitation with Flag-M2 antibody and then 
immunoblotted with rabbit anti-Flag antibody. The expression of HA-tagged WT-MELK in total cell lysates was confirmed by western blotting analy-
sis. As a control, immunoprecipitation was performed from cells co-transfected with pCAGGSn3FC (Mock) and HA-tagged WT-MELK (HA-WT-
MELK) through all steps. Arrowheads indicate expression of each Bcl-GL peptide.Breast Cancer Research    Vol 9 No 1    Lin et al.
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pression of full-length Bcl-GL  (HA-Mock+Flag-Bcl-GL)
significantly increased the proportion of TUNEL-positive cells
compared with the cells transfected with the mock plasmids
(HA-Mock+Flag-Mock), indicating that Bcl-GL induces apop-
tosis, as described previously [14]. In contrast, the co-overex-
pression of WT-MELK with Bcl-GL (HA-WT-MELK+Flag-Bcl-
GL) reduced the proportion of TUNEL-positive cells compared
with over-expression of Bcl-GL alone (HA-Mock+Flag-Bcl-GL)
(P = 0.0001, unpaired t-test). However, the co-overexpression
of D150A-MELK with Bcl-GL  (HA-D150A-MELK+Flag-Bcl-
GL) did not affect the proportion of TUNEL-positive cells. As
shown in Figure 5d, FACS analysis of the cells under the same
conditions also confirmed that the overexpression of Bcl-GL
increased the sub-G1 population of cells compared with the
mock-transfected cells. Similarly to the TUNEL analysis, the
overexpression of WT-MELK with Bcl-GL reduced the propor-
tion of sub-G1 cells (P = 0.03, unpaired t-test), while D150A-
MELK increased the sub-G1 population. Our results imply that
the kinase activity of MELK may play a critical role in the regu-
lation of the pro-apoptotic function of Bcl-GL.
Discussion
Microarray technologies applied to the study of cancer have
contributed to the discovery of genes that play essential roles
in carcinogenesis, the discovery of novel molecular target(s)
for the development of anti-cancer agents and/or diagnosis,
and the identification of genes related to chemo- or radio-sen-
sitivity. Although such information has been applied in the
development of novel therapeutic agents for breast cancer,
the range of available treatments for advanced-stage patients
Figure 4
MELK phosphorylates Bcl-GL in vitro MELK phosphorylates Bcl-GL in vitro. (a) Immunoprecipitates were subjected to immune complex kinase assay with wild-type (WT)-MELK or kinase-
dead (D150A)-MELK). The single arrowhead indicates phosphorylated Bcl-GL, and the double arrowhead points to an autophosphorylated MELK 
protein. (b) Phosphorylation of a bacterial glutathione S-transferase (GST) Bcl-GL fusion recombinant protein (GST-Bcl-GL) by His-tagged WT-
MELK (WT). The single arrowhead indicates phosphorylated GST-Bcl-GL protein, and the double arrowhead indicates an autophosphorylated His-
tagged MELK protein. (c) In vitro phosphorylation of various partial amino-terminal constructs of Bcl-GL (N-1, N-2, N-3 and N-4; see Figure 3e) and 
full-length Bcl-GL (FL) by MELK. The single arrowheads indicate phosphorylated immunoprecipitated Bcl-GL proteins, and the double arrowhead 
indicates an autophosphorylated MELK recombinant protein.Available online http://breast-cancer-research.com/content/9/1/R17
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is still very limited. Thus, it is urgent that further molecular
targets are discovered to enable development of new anti-can-
cer drugs that are specific for malignant cells with a minimum
risk of adverse reactions.
Using genome-wide expression profiles of breast cancers and
normal human tissues [8,9], we identified MELK, one of the
transcripts of which was specifically up-regulated in the great
majority of clinical breast cancer samples, but expressed in
none of 29 normal human tissues examined except testis, thy-
mus and small intestine.
In this study, we characterize the biological function of MELK
and indicate that it would be a good candidate as a molecular
target for breast cancer therapy, although there would be
some concerns over intestinal adverse reactions. We demon-
strated by means of siRNA that knockdown of endogenous
MELK expression results in growth suppression of breast can-
cer cells (Figure 2). Furthermore, our cDNA microarray data
indicate that MELK is also up-regulated relatively frequently in
bladder cancers, osteosarcoma and small cell lung cancers
(data not shown). Together, these findings suggest that MELK
has an oncogenic role in not only breast cancers but also blad-
der cancers, bone cancers and small cell lung cancers.
Figure 5
MELK involvement in the apoptosis cascade through Bcl-GL MELK involvement in the apoptosis cascade through Bcl-GL. HA (hemagglutinin)-tagged MELK (HA-wild-type (WT)-MELK or HA-kinase-dead 
(D150A)-MELK) and Flag-tagged Bcl-GL (Flag-Bcl-GL) expression vectors were co-transfected into COS7 cells for 24 hours. (a) The expression of 
MELK and Bcl-GL proteins in the co-transfected cells were examined by western blot analysis. (b) TUNEL assays after transfection with 
pCAGGSnHC (HA-Mock), pCAGGSn3FH (Flag-Mock), HA-tagged MELK (WT and D150A), Flag-tagged Bcl-GL expression vectors, and combina-
tions of these. Apoptotic cells were measured by counting of TUNEL staining (means ± standard deviation, n = 3; P = 0.0001; unpaired t-test). (c) 
Representative images of TUNEL assays. Cells were labeled with DAPI (4',6-diamidino-2-phenylindole) for counting of total cell number. Apoptotic 
cells with DNA strand breaks were labeled with green fluorescence. (d) FACS analysis of cells collected after transfection with pCAGGSnHC (HA-
Mock), pCAGGSn3FH (Flag-Mock), HA-tagged MELK (WT and D150A), Flag-tagged Bcl-GL expression vectors, and combinations of these. Pro-
portions of apoptotic cells are indicated as percentages of sub-G1 populations. Each value represents the average of three experiments (means ± 
standard deviation, n = 3).Breast Cancer Research    Vol 9 No 1    Lin et al.
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MELK was previously identified as a new member of the snf1/
AMPK serine-threonine kinase family that is involved in mam-
malian embryonic development [15-18]. This gene was shown
to play an important role in hematopoiesis, stem cell renewal
[19] and cell-cycle progression through an interaction with
zinc finger-like protein ZPR9 [20] and splicing factor NIPP1
[12]. To investigate the expression pattern of these proteins in
breast cancer cells, we performed semi-quantitative RT-PCR,
and observed no significant correlation of gene expression
between MELK and these interacting molecules in breast can-
cer cells (data not shown). Thus, to investigate the biological
significance of MELK in breast cancer cells, we searched for
a possible substrate(s) of MELK by means of in vitro pull-down
assays with recombinant wild-type MELK (WT-MELK) and
kinase-dead MELK (D150A-MELK). We identified a long iso-
form of Bcl-G (Bcl-GL), a pro-apoptotic member of the Bcl-2
family, as a potential substrate for MELK. In addition to physi-
cal interaction between these two proteins, in vitro immune
complex kinase and in vitro binding assays showed that Bcl-
GL was directly bound to MELK and specifically phosphor-
ylated by it in vitro (Figures 3d and 4a,b).
As reported previously [14], we demonstrated by TUNEL
assay and FACS analysis that introduction of full-length Bcl-
GL into COS7 cells induced apoptosis. However, under the
same conditions, addition of exogenous WT-MELK sup-
pressed induction of apoptosis by Bcl-GL, but addition of
D150A-MELK did not (Figure 5b–d). Thus, we speculate that
MELK might promote cell growth by inhibiting the pro-apop-
totic function of Bcl-GL through its phosphorylation.
Conclusion
Our findings clearly suggest that MELK is overexpressed in
both breast cancer specimens and cancer cell lines, and that
its kinase activity possibly plays a significant role in breast can-
cer cell growth. Recent anti-cancer drug development is
focused on targeting important molecules involved in the
oncogenic pathways, represented by imatinib mesylate and
trastuzumab. We found that down-regulation of MELK  by
treatment with siRNA significantly suppressed the cell growth
of breast cancer, indicating its crucial role in the proliferation
and tumorgenesis of breast cancer. In particular, we demon-
strate a new biological function for MELK in breast carcino-
genesis, the inhibition of apoptosis though its interaction with
and phosphorylation of Bcl-GL, a pro-apoptotic member of
Bcl-2 family. Our data should contribute to a better under-
standing of breast carcinogenesis, and they suggest that
MELK  is a promising molecular target for breast cancer
treatment.
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